CVL237 Tablets in the Treatment of Advanced Solid Tumors With PTEN Deficiency
Status:
Not yet recruiting
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter, phase II study of CVL237 tablets in the
treatment of advanced solid tumors with PTEN deficiency. It is planned to enroll patients
with PTEN deficiency advanced solid tumors of different tumor types (PTEN deficiency gastric
cancer, prostate cancer, endometrial cancer, colorectal cancer, lung cancer, breast cancer
and melanoma etc.) to evaluate the preliminary efficacy, safety and pharmacokinetic profile
of CVL237 tablets in patients with PTEN deficiency advanced solid tumors of different tumor
types.